https://www.aafp.org/patient-care/clinical-recommendations/all/prostate-cancer.html. 2012. Accessed March 8, 2018. 40. Bell N, Connor Gorber S, Shane A, et al; Canadian Task Force on Preventive Health Care. Recommendations on screening for prostate cancer with the prostate-specific antigen ...
The American Cancer Society (ACS) recommends PSA screening for all men over age 50 and at age 45 for men at higher risk (e.g., men with a family history of prostate cancer and African-American men). Similar recommendations have been issued by the American Urological Association (AUA) and ...
Implications of the New USPSTF Prostate Cancer Screening Guideline JAMA Internal Medicine Editorial July 1, 2018 USPSTF Prostate Cancer Screening Recommendations—A Step in the Right Direction JAMA Surgery Editorial August 1, 2018 A New Prostate Cancer Screening Recommendation JAMA Oncology Editorial August...
Despite the publication of thousands of articles on PSA and pros- tate cancer screening, the value of early intervention remains unclear.2,3 The PCA3 gene, formerly known as DD3, was first identified in 1999.2 PCA3 is a non–protein-coding messenger RNA (mRNA) that is highly overexpressed ...
Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen for therapeutic targeting in prostate cancer. Here, we report broad expression of STEAP1 relative to prostate-specific membrane antigen (PSMA) in lethal metastatic
Background Given the public health relevance of PSA-based screening, various professional organizations have issued recommendations on the use of the PSA test to screen for prostate cancer in different age groups. Aim Using a large commercial claims database, we aimed to determine the most recent ...
Talk to your doctor about the risks and benefits ofprostate cancer screeningand having PSA testing if you are 40 years of age with a family history of prostate cancer (or age 50 if you do not have a family history), or are of African-American ancestry. The test results should be conside...
Early-onset prostate cancer (EOPC, ≤ 55 years) has a unique clinical entity harboring high genetic risk, but the majority of EOPC patients still substantial opportunity to be early-detected thus suffering an unfavorable prognosis. A refined understanding of age-based polygenic risk score (PRS)...
With the widespread use of prostate cancer screening tests, over 60% of men with prostate cancer may not have any symptoms at the time of diagnosis. Instead, the only sign of the disease may be an elevated prostate-specific antigen (PSA) level. For some men, the tumor can be felt during...
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384: 2027–2035. 4 Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening ...